Editas Medicine Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, and it's my pleasure to introduce our next company, Editas Medicine and CEO, Cindy Collins.
Please note that following this presentation, we will have a Q&A session where you have the ability to submit questions via the conference portal. So with that, Cindy, thank you for being here today, and let me turn things over to you.
Thank you, Cory, and the JPMorgan team for the opportunity to speak today. Next slide. I would like to draw your attention to the fact that this presentation contains forward-looking statements. We encourage you to review potential risks and uncertainties outlined in our most recent 10-Q and 10-K, which are on file with the SEC. Next slide. Last year was a revolutionary year for gene editing.
There were important accomplishments and remarkable strides made towards potentially curative medicines for what were once thought to be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |